Financings Of The Fortnight: Cardiome's Reticence The Exception During Busy Spate Of Deals
This article was originally published in The Pink Sheet Daily
Executive Summary
Highlighting this edition is a pair of privately held genomic sequencing companies that raised funds in new venture rounds.
You may also be interested in...
Deals Of The Week: Roche/Galaxy, Mallinckrodt/CNS Therapies, Valeant/QLT
Cardiome may go it alone with atrial fibrillation drug vernakalant after Merck exited a 2009 partnership around the drug, but another possibility is that Cardiome will seek a buyer.
Cell Therapeutics' Pixantrone Advisory Committee May Include Updated Results Of Pivotal Trial
FDA declined to give the NME for recurring, aggressive non-Hodgkin's lymphoma priority review, but the firm hopes that progression free survival data and safety argument will be compelling to ODAC.
Cell Therapeutics' Pixantrone Advisory Committee May Include Updated Results Of Pivotal Trial
FDA declined to give the NME for recurring, aggressive non-Hodgkin's lymphoma priority review, but the firm hopes that progression free survival data and safety argument will be compelling to ODAC.